Charcot neuroarthropathy—also called Charcot foot or Charcot neuro-osteoarthropathy (CNO)—is one of the most consequential yet frequently missed complications of diabetes. It describes a progressive breakdown of the bones and joints of the foot and ankle in a limb that has lost protective sensation. Because the early presentation can be mistaken for infection, gout, or a simple sprain, delayed recognition is common and can lead to permanent deformity, ulceration, and in the worst cases, amputation. Understanding how Charcot foot develops, how it is diagnosed, and why early offloading matters is essential for anyone caring for a person with diabetic neuropathy.
Why the Charcot Foot Develops
Charcot neuroarthropathy occurs almost exclusively in feet affected by peripheral neuropathy. In reported cohorts, the overwhelming majority of patients have diabetes and neuropathy, with a substantial minority also having peripheral arterial disease. The pathophysiology is best understood as a convergence of two long-standing theories. The neurotraumatic theory holds that loss of protective sensation allows repetitive, unperceived trauma—microfractures and joint injury accumulate because the patient feels no warning pain. The neurovascular theory proposes that autonomic neuropathy increases blood flow through arteriovenous shunting, promoting bone resorption and weakening the skeleton.
Modern research has added a molecular layer to these ideas. A local inflammatory cascade, driven by pro-inflammatory cytokines such as TNF-α and IL-1β, amplifies signaling through the RANKL–RANK–osteoprotegerin (OPG) pathway. Overexpression of RANKL drives osteoclast activation and unchecked bone resorption without a matching increase in bone formation, producing the low bone density and fragility characteristic of the acute phase. A minor injury in this setting can trigger a cycle of fracture, inflammation, and further destruction.
Recognizing the Acute Charcot Foot
The acute Charcot foot classically presents as a red, hot, and swollen foot in a person with long-standing neuropathy—often without an open wound and frequently without significant pain. A useful clinical clue is that the erythema tends to diminish when the leg is elevated. Skin temperature is a practical marker: the affected foot is typically several degrees warmer than the opposite foot, and this temperature difference is used both to support the diagnosis and to monitor treatment.
The central diagnostic challenge is distinguishing Charcot from infection, since both can produce warmth, redness, and swelling. Misdiagnosis is strikingly common; studies have reported that a majority of patients are initially misdiagnosed, with symptoms present for a median of roughly two months before Charcot is correctly identified. Plain radiographs may show joint destruction, fragmentation, subluxation, or dislocation, but they can appear normal very early. When x-rays are inconclusive, MRI is valuable for detecting the bone marrow edema and subtle changes of early disease and for helping differentiate Charcot from osteomyelitis. In 2023 the International Working Group on the Diabetic Foot (IWGDF) published its first dedicated guideline on the diagnosis and treatment of active Charcot neuro-osteoarthropathy, underscoring how important early, systematic recognition has become.
Treatment: Offloading Is the Priority
Offloading during the acute, active stage is the single most important intervention and can arrest progression before permanent deformity develops. The standard of care is immobilization in an irremovable total contact cast (TCC). Early in treatment the cast is changed frequently—often within the first few days as swelling declines—and then reviewed at regular intervals. Casting continues until the acute inflammation resolves, judged by reduction in swelling and by the skin temperature of the affected foot coming within about 2°C of the other foot.
Resolution is gradual and treatment is often lengthy, spanning many weeks to months. Because premature return to unprotected weight-bearing risks relapse, transition out of the cast is staged and cautious; even with careful criteria, a meaningful proportion of patients experience recurrence, which is why long-term protective footwear and monitoring are recommended after the acute phase settles.
When Surgery Is Considered
Most acute Charcot feet without skin breakdown are managed non-operatively. Surgical reconstruction is generally reserved for feet with severe or unstable deformity, recurrent ulceration over bony prominences, or infection that cannot be controlled with offloading and wound care alone. The overarching surgical goal mirrors the conservative one: a stable, plantigrade foot that can be safely fitted with footwear and used for walking without recurrent ulceration.
Key Takeaways
Charcot neuroarthropathy is a limb-threatening emergency that hides behind unremarkable symptoms. In any person with diabetic neuropathy, a warm, swollen foot should be treated as active Charcot until proven otherwise, even in the absence of a wound or pain. Early diagnosis—supported by temperature comparison and, when needed, MRI—combined with prompt, sustained offloading in a total contact cast offers the best chance of preserving a functional foot. Recognizing the pattern early is what separates a foot that heals in a stable shape from one that progresses to disabling deformity.
References
Senneville É, et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes/Metabolism Research and Reviews, 2023.
Rogers LC, Frykberg RG, Armstrong DG, et al. The Charcot Foot in Diabetes. Diabetes Care, 2011;34(9):2123–2129.
Kaura R, et al. RANKL-RANK-OPG Pathway in Charcot Diabetic Foot: Pathophysiology and Clinical-Therapeutic Implications. International Journal of Molecular Sciences, 2023.
Dodd A, Daniels TR. Charcot Neuroarthropathy of the Foot and Ankle. Review of key concepts, diagnosis, and management, 2018–2024.
Wukich DK, et al. Duration of total contact casting for resolution of acute Charcot foot: a retrospective cohort study. 2021.
Comments
